Bristol Myers Squibb Company

Introduction
Bristol Myers Squibb (BMS) is a leading American biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for serious diseases. Formed in 1989 through the merger of Bristol-Myers Company and Squibb Corporation, BMS is renowned for its pioneering work in oncology, cardiovascular health, immunology, and hematology. The company has become a global leader in immuno-oncology with its flagship medicine Opdivo.

Mission and Vision

Mission: To discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Vision: To transform patients’ lives through science, becoming the world’s leading biopharmaceutical company.

Products and Services

Oncology & Hematology: Opdivo (immuno-oncology), Yervoy (melanoma), Revlimid, Pomalyst, and Breyanzi.
Cardiovascular: Eliquis, a leading oral anticoagulant.
Immunology: Treatments for rheumatoid arthritis, psoriasis, and other immune disorders.
Cell Therapy: CAR-T therapies targeting hematologic cancers.
Pipeline Innovation: Focus on next-generation biologics, cell therapy, and precision medicine.

Growth and Innovation
BMS has significantly expanded through strategic acquisitions, most notably the $74 billion acquisition of Celgene in 2019, strengthening its oncology and hematology portfolio. The company continues to invest in cell therapy, immuno-oncology, and precision medicine, solidifying its role as a pioneer in advanced therapies. BMS is also leveraging digital health and AI to accelerate drug development.

Global Impact
Operating in more than 60 countries, BMS medicines reach millions of patients worldwide. The company is particularly impactful in cancer treatment, helping transform oncology care globally. Its strong cardiovascular and immunology portfolios also contribute to improving long-term patient health. BMS supports global health initiatives, patient access programs, and sustainability commitments to reduce environmental impact.